10/10/2007

Device firm Angiotech Pharmaceuticals said it plans to file a premarket notification with the FDA for its 5-Fluorouracil-coated Central Venous Catheter after positive clinical trial results. The company said the 5-FU drug is intended to prevent bacterial growth in implanted catheters.

Related Summaries